Bischoff, J., & Marmé, F. (2016). A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab pre-treated patients with Her2-positive metastatic breast cancer - E-Vita -. Annals of oncology, 27, . https://doi.org/10.1093/annonc/mdw365.52
Chicago-Zitierstil (17. Ausg.)Bischoff, Joachim, und Frederik Marmé. "A Randomized Phase II Study to Determine the Efficacy and Tolerability of Two Doses of Eribulin Plus Lapatinib in Trastuzumab Pre-treated Patients with Her2-positive Metastatic Breast Cancer - E-Vita -." Annals of Oncology 27 (2016). https://doi.org/10.1093/annonc/mdw365.52.
MLA-Zitierstil (9. Ausg.)Bischoff, Joachim, und Frederik Marmé. "A Randomized Phase II Study to Determine the Efficacy and Tolerability of Two Doses of Eribulin Plus Lapatinib in Trastuzumab Pre-treated Patients with Her2-positive Metastatic Breast Cancer - E-Vita -." Annals of Oncology, vol. 27, 2016, https://doi.org/10.1093/annonc/mdw365.52.